Advanced & Next-Gen Proteomics - Head of Proteomics Core Lab, West Coast Research University

An AMC researcher primarily using mass spec for the development, manufacturing and quality control of biologic therapeutics, target validation, and metabolomics. This stakeholder remarks that, of current so-called next-generation proteomics platforms, few are truly doing anything new or unique; in their opinion, the term next-generation should be reserved for technologies such as that promised by Quantum-Si, i.e., the ability to sequence unknown proteins de novo, with high amino acid sequence resolution. Nautilus, Encodia, and Seer are other players, though none are yet validated. While the goal of true protein sequencing is impeded by numerous biophysical challenges, a true next-generation proteomic platform adds far more value than existing, antibody recognition-based approaches. Of the existing antibody-based platforms,Standard BioTools / Fluidigm was seen as attractive. The most important criteria for proteomics offerings are, in this stakeholder’s view, specificity, instrument price, and price per assay.